How does Gilead’s Trodelvy first-line TNBC approval affect TROP2 ADC competition?

Gilead’s Trodelvy gained FDA approval for first-line triple-negative breast cancer use regardless of PD-L1 status, positioning it directly against AstraZeneca and Daiichi Sankyo’s Datroway. This PD-L1-agnostic label broadens Trodelvy’s eligible patient pool, giving Gilead a commercial edge as both companies vie for leadership in the TROP2 ADC market.